Leishmania major soluble exo-antigens (LmSEAgs) protect neonatal BALB/C mice from a subsequent challenge with L. major and stimulate cytokine production by Leishmania-naïve human peripheral blood mononuclear cells.
The vaccine potential and immunogenicity of soluble Leishmania major exo-antigens (LmSEAgs), a potentially novel source for vaccine candidates for leishmaniasis, were evaluated in neonatal BALB/c mice and with human peripheral blood mononuclear cells. Vaccinated neonatal BALB/c mice resisted infection with L. major, and lymphoid cells from the mice proliferated when restimulation with LmSEAgs and produced interferon-gamma and some interleukin-4. In addition, LmSEAgs stimulated human peripheral blood mononuclear cells to produce large amounts of interferon-gamma and some interleukin-5. This finding suggests that LmSEAgs may be a vaccine candidate for leishmaniasis in humans.